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Abstract Maintaining the functional integrity of mito-
chondria is pivotal for cellular survival. It appears that
neuronal homeostasis depends on high-fidelity mitochon-
dria, in particular. Consequently, mitochondrial dysfunction
is a fundamental problem associated with a significant
number of neurological diseases, including Parkinson’s
disease (PD), Huntington’s disease (HD), Alzheimer’s
disease (AD), amyotrophic lateral sclerosis (ALS) and
various peripheral neuropathies, as well as the normal aging
process. To ensure optimal mitochondrial function, diverse,
evolutionarily conserved mitochondrial quality control
mechanisms are in place, including the scavenging of toxic
reactive oxygen species (ROS) and degradation of damaged
mitochondrial proteins, but also turnover of whole organ-
elles. In this review we will discuss various mitochondria-
associated conditions, focusing on the role of protein
turnover in mitochondrial maintenance with special
emphasis on neurodegenerative disorders.
Introduction
The involvement of mitochondria and their dysfunction in
the pathogenic context of neurological disorders has been
extensively debated and is now generally accepted [23,
110]. While mitochondria have long been known for their
role in ATP generation through oxidative phosphorylation
(OxPhos), many more diverse (patho)physiological roles
for these organelles have been described during the last two
decades. The traditional view of mitochondria as power-
houses quietly lingering around/resting in the cytosol of
cells is now replaced by the perspective of a dynamic
mitochondrial network that not only physically connects
remote cellular compartments (such as neuronal synapses)
to the soma but which is also intrinsically involved in
major cellular life and death decisions [99, 129]. Beyond
ATP generation, mitochondria are also involved in a
number of critical pathways, including the buffering of
calcium ions [89], lipid metabolism [35], the synthesis of
iron-sulfur clusters [105], and the regulation of pro-
grammed cell death [137].
This deep integration of mitochondria into cellular
physiology is reflected by the sometimes dramatic conse-
quences linked to mitochondrial dysfunction. Physiological
aging as well as age-related diseases are frequently asso-
ciated with decreased mitochondrial function. Thus,
diverse maintenance mechanisms, operating to keep mito-
chondria in a peak functional state, are of uttermost
importance to prevent mitochondrial dysfunction-linked
diseases, premature aging and associated cell death.
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Mitochondrial damage and neurodegeneration:
targets and triggers
Overview
Mitochondria are thought to be remnants of an ancient
endosymbiotic event between an anaerobic, glycolytic
eubacterium and an a-proteo bacterium around 1.5–2 bil-
lion years ago that formed modern aerobic eukaryotic cells
[52, 57, 107]. The presence of bacterial chromosome-like,
circular mitochondrial DNA (mtDNA), a bacterial-type
protein translation apparatus, and the double membrane
similar to that found in a-proteo bacteria still bear witness
of this union. This symbiotic relationship, while obviously
beneficial, comes with its own set of challenges. Whereas
the mitochondrial proteome consists of at least 1,000 pro-
teins [100], mtDNA only codes for 13 of these proteins [6].
Through mitochondrial gene-transfer to the host cell gen-
ome, the vast majority of originally a-proteo bacterial
proteins is translated in the cytosol and has to be imported
into mitochondria. Since the mitochondrial electron trans-
port chain (ETC) consists of large multi-protein complexes
with their subunits encoded by both the nuclear and
mitochondrial genomes, nuclear as well as mitochondrial
protein expression has to be tightly coordinated to avoid
the production of superfluous and potentially harmful ETC
subunits. Mitochondrial DNA is organized in a large, cir-
cular, plasmid-like chromosome devoid of introns and
histons, with each mitochondrial subunit harboring several
hundred individual copies organized in so-called nucleoids
located in the mitochondrial matrix compartment. Each
nucleoid contains on average 1.4 copies of mtDNA, and
although histones are not present, other proteins coat the
mtDNA and seem to confer some protection [14, 78]. Since
the matrix-enclosing inner mitochondrial membrane
(IMM) is the site of OxPhos, mtDNA is in close vicinity to
the toxic by-products of OxPhos in the form of reactive
oxygen species (ROS) [18]. Although a wide variety of
DNA repair mechanisms that act on mtDNA are in place
[13], clonal analyses of aged cells show the expansion of
large mtDNA deletion mutants in single cells causing
ultimately failure of the ETC as evidenced by isolated
cytochrome c oxidase negative muscle fibers [48]. But
DNA is not the only target for oxidative damage. Proteins
are also susceptible to modification, for example carbon-
ylation [37], rendering them inactive, thus potentially
impacting proper mitochondrial function [38].
Mitochondrial energy production
The components of the ETC is responsible for the transfer
of electrons from nutrients to oxygen are localized in the
IMM [118]. Unlike most other cell types, neurons are
unable to meet their energy needs through glycolysis alone,
and therefore are particularly dependent on a highly effi-
cient ETC [113]. Consequently, insufficient mitochondrial
energy production, caused by mutations impairing OxPhos
components, is linked to mitochondrial disorders such as
LHON (Leber’s hereditary optic neuropathy), MELAS
(mitochondrial myopathy, encephalopathy, lactic acidosis,
and stroke-like episodes), MERRF (myoclonic epilepsy
with ragged red fibers), Kearns-Sayre syndrome or CPEO
(chronic progressive external ophthalmoplegia). These
diseases manifest themselves with neurological symptoms
such as loss of vision, deafness, ataxia, seizures, external
ophthalmoplegia, and cognitive impairment, but also
muscle weakness [20, 21, 29, 87]. However, mutations
directly affecting mitochondrial energy production (mostly
mtDNA mutations) comprise a relatively small number of
neurodegenerative diseases. This is in contrast to the large
number of patients affected with sporadic, late-onset neu-
rodegenerative disorders such as Parkinson’s (PD),
Alzheimer’s (AD) or Huntington’s disease (HD). Although
failure of mitochondrial energy production is associated
with late-onset neurodegenerative diseases, it is still under
debate whether diminished mitochondrial function is the
primary cause of the disease. It is possible that subtle
disturbances in mitochondrial maintenance and/or (protein)
quality control, perhaps induced by dysfunctions in other
cellular pathways, may over extended periods of time result
in the accumulation of low-fidelity mitochondria unable to
maintain sufficient ATP levels, thus leading to neuronal
cell degeneration.
Oxidative stress
Closely linked to mitochondrial energy production, oxi-
dative stress caused by mitochondrial reactive oxygen
production (ROS) is often considered an underlying cause
of neurodegeneration [81]. Mitochondria consume large
amounts of oxygen during oxidative phosphorylation.
Leakage of electrons from the ETC results in the genera-
tion of superoxide anions (O2
-) and, consequently, in ROS
such as hydrogen peroxide or hydroxyl radicals [18]. These
highly reactive species are capable of damaging proteins,
membrane lipids, and DNA. Since the generation of O2
-
during OxPhos appears to be unavoidable and is quasi an
occupational hazard for mitochondria, several defense
mechanisms, including ROS scavengers and ROS con-
verting enzymes, are in place to deal with free radicals
[117] and damaged proteins or DNA, respectively [13,
122]. It is estimated that up to 2% of all electrons trafficked
through the ETC are transferred prematurely to oxygen in
one-electron reduction reactions causing the formation of
superoxide (O2
-) in a process called electron leakage [18],
although this value might be much lower in properly
158 Acta Neuropathol (2012) 123:157–171
123
functioning mitochondria in vivo. Oxidative stress occurs
after the antioxidant defense is overwhelmed and damage
to proteins and DNA occurs. A sub-par working ETC now
is a major source of electrons available for transfer to
molecular oxygen [125] and an already damaged ETC
might incur even more oxidative damage causing a vicious
cycle that results in even more ROS production [7]. In
addition, under this scenario, oxidatively damaged mtDNA
would increase generation of mutated ETC components,
thus further increasing ROS production. This hypothesis
was first formulated by Harman [61] and ultimately led to
the free radical theory of aging in the mid-fifties. However,
this ‘‘vicious cycle’’ hypothesis has recently been chal-
lenged [124], and it is unclear to what degree
mitochondrial ROS can cause sufficient mtDNA damage to
impact the ETC in such a way that electron leakage is
increased [53]. Interestingly, single cell analyses of
mtDNA mutations revealed that individual cells contain
one particular mtDNA mutation (instead of various random
mutations) independently of the mutations found in
neighboring cells in aged tissue [17, 48]. In addition,
although the so called ‘‘mutator mouse’’ with an increased
mtDNA mutation rate did show signs of premature aging,
no elevated levels of ROS or oxidative damage were
observed [124]. While these observations would argue
against the ‘‘vicious cycle’’ hypothesis, it would support
aging through accumulated mtDNA damage. Nonetheless,
under certain conditions, increased ROS production is
linked to neurodegeneration as exemplified below.
Friedreich’s ataxia (FA), caused by mutations in the
gene coding for the mitochondrial protein frataxin [19], is
an example of a neurodegenerative disorder linked to
increased oxidative stress and ROS production [75]. Acting
as a chaperone in mitochondrial iron transport, frataxin
serves important functions in the biogenesis of iron–sulfur
clusters essential for ETC and tricarboxylic cycle function
[102]. In patients afflicted with Friedreich’s ataxia,
silencing mutations result in decreased frataxin activity,
causing the accumulation of Fe(II) in mitochondria, which
in turn leads to increased ROS production. Interestingly,
treatment of early stage FA patients with idebenone, an
analog of the ETC component coenzyme Q10 results in an
alleviation of neurological symptoms [56]. Another
prominent link between increased ROS production and
neurodegeneration is exemplified by toxins such as
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the
herbicide paraquat, or the pesticide rotenone, all known
inhibitors of ETC complex I. While there is still insuffi-
cient epidemiological data linking, e.g., chronic paraquat
exposure to neurodegeneration associated with PD, acute
exposure to MPTP causes PD-like symptoms in humans. In
addition, these complex I inhibitors are widely used in
inducible PD models in rodents [11].
In addition to the above-discussed conditions of PD and
FA, Leber’s hereditary optic neuropathy (LHON) impres-
sively highlights the link between energy production,
oxidative stress and neurodegeneration. LHON, occurring
at a prevalence of up to 1:20,000 in certain areas of Europe,
is usually caused by one of three mutations in subunits
within the NADH dehydrogenase (ETC complex I) [123].
The disease exhibits a maternal inheritance as expected
from mtDNA-based disease mutations. In addition, LHON
exhibits a strong male bias at a low penetration (up to 50%
in males; around 10% in females) whose basis is still
unclear [123]. Interestingly, the mitochondrial DNA-
haplogroup background seems to influence the clinical
expression of LHON mutations [65]. In most cases, LHON
occurs isolated to the optic nerve, with only a small sub-
group of patients displaying a plus-phenotype with
additional neurological symptoms such as cerebellar ataxia
or encephalomyopathy [58, 88, 95]. Intriguingly, depend-
ing on the underlying disease causing mtDNA mutation,
some patients experience partial vision recovery even
several years after disease onset [2]. Why LHON affects
both eyes simultaneously (or over a short period of time) in
mostly young, male adults is not clear. Although analyses
of cells harboring LHON mutations did reveal a reduction
of the respiratory capacity in the case of phenotypically
more severe mutations, ROS production seemed elevated
in LHON cells, independently of the underlying mutation
[138]. In addition, the pronounced male bias and the sud-
den, mostly bilateral onset suggest additional genetic but
also environmental factors. Indeed, a role for smoking in
triggering LHON onset was found [74], supporting the
notion that excess ROS production may be an important
factor in LHON pathogenesis. This notion gains further
support by the fact that antioxidant treatment may shorten
the interval between disease onset and potential vision
recovery [85], although final proof for such treatment of
LHON is still not available [9].
Misfolded proteins
It is well established that in various neurodegenerative
diseases, misfolded proteins [e.g., mutated superoxide dis-
mutase in amyotrophic lateral sclerosis (ALS), mutant
huntingtin in HD or b-amyloid peptide in AD] accumulate
on mitochondria and cause the functional decline of these
organelles [47, 50, 80, 109, 128]. Recent evidence indicates
that accumulation of misfolded proteins on mitochondria
can lead to various functional defects of these organelles,
including inhibition of mitochondrial fusion, bioenergetic
defects as well as abnormal apoptosis [47, 49, 50, 109, 130].
Interestingly, the evidence indicates that mitochondrial
accumulation of ALS-linked mutant superoxide dismutase
1 (mSOD1) leads to dramatic changes in the proteome of
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spinal cord mitochondria [80]. ALS exhibits fast progress-
ing muscle weakness caused by the degeneration of upper
and lower motor neurons. It has been found that upon
exposure to mSOD1, levels of*50 mitochondrial proteins,
including several ETC components, as well as mitochon-
drial fusion factor Mfn2 were altered, indicating a possible
widespread effect of mSOD1 on mitochondrial function.
Furthermore, although observed decreases in some of the
mitochondrial proteins were attributed to mSOD1-induced
inhibition of mitochondrial protein import, increases in the
levels of several other proteins were also detected. It is
tempting to speculate that accumulation of ‘‘foreign’’ toxic
proteins on the surface of mitochondria might also affect
mitochondrial protein turnover, leading to further distur-
bances in mitochondrial proteostasis.
PD-causing misfolded a-synuclein mutants—that like
mSOD1 have also been shown to associate with the cyto-
plasmic site of the OMM and to induce mitochondrial
dysfunctions [90]—did not affect spinal cord mitochondria
in a similar to mSOD1 fashion. Thus, the question remains
of how disease-linked mutant proteins effect mitochondrial
function. However, alternative mechanisms underlying
mSOD1-induced mitochondrial toxicity, including inhibi-
tion of the voltage-dependent anion channel (VDAC),
activation of apoptosis, as well as ETC impairments, have
also been described for other mitochondria-toxic proteins,
including mutant huntingtin and a-synuclein mutant [47,
49, 50, 69, 109, 130] suggesting a common pathogenic
theme involving mitochondria. Further extending the
complexity of misfolded protein-induced mitochondrial
defects, a number of reports indicate that mitochondrial
fusion and fission are also affected by the exposure to these
toxic factors [90, 112, 115, 128, 130, 131]. Importantly,
either physical interaction with proteins implicated in
mitochondrial fusion or fission or direct association with
the OMM appears to be important for mitochondrial
dynamics impairment by mutant huntingtin [112, 115,
130], a-synuclein [90], b-amyloid [131] and mSOD1 [128],
indicating a close relationship between misfolded protein-
induced mitochondrial dysfunction and mitochondrial
fusion and fission machineries [36]. To sum up, although
the data strongly suggest that mitochondrial activity is
directly affected by abnormal accumulation of neurode-
generation-linked mutant proteins, the precise scenario of
the events, including primary triggers and the extent to
which mitochondrial defects contribute to disease patho-
genesis remain to be established.
Degradation of mitochondrial proteins
Maintenance of mitochondrial proteostasis is best per-
ceived as a three-tiered mechanism [122] (Fig. 1). Through
the first mechanism, damaged mitochondrial networks and
cells hosting them are removed by the induction of apop-
totic cell death pathways [79]. The second tier is
represented by the intracellular recycling/elimination of
entire dysfunctional mitochondria through mitophagy, a
mitochondria-specific form of autophagy [1, 73], with the
underlying molecular pathways being discussed in the
context of neurodegenerative disorders in the accompany-
ing article by Winklhofer (this issue). Another mechanism
of mitochondrial protein quality control—targeted protein
degradation or proteolytic processing of mitochondrial
proteins and its connection to neurological disorders—will
be covered in this review. It should be pointed out, though,
that these three levels of mitochondrial quality control do
not act autonomously, but are instead tightly linked to basic
physiological processes including mitochondrial morphol-
ogy regulation.
To maintain cellular and mitochondrial homeostasis,
adjusting the protein inventory to cellular needs and
removing superfluous and damaged proteins is essential.
Several protein processing and degradation mechanisms
are in place to perform protein quality control and ensure
proper mitochondrial function (Fig. 2).
Protein degradation in the mitochondrial matrix
The mitochondrial matrix is the site of the citric acid
(Krebs) cycle responsible for generating reduction equiv-
alents for use in the ETC across the IMM. Thus, protein
quality control in the matrix is crucial for maintaining
mitochondrial ATP production. Due to the close proximity
of matrix components to the ROS producing complexes of
the ETC, major oxidative damage to matrix resident pro-
teins can occur. The enzyme aconitase, responsible for the
conversion of citrate via cis-aconitate to iso-citrate in the
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Fig. 1 Mitochondrial quality control. Several mechanisms are in
place to prevent runaway mitochondrial damage in order to maintain
respiratory competence. Continuous removal of damaged proteins
paired with the autophagic digestion of non-functional mitochondrial
subunits uphold overall mitochondrial respiration. Extensive mito-
chondrial damage leads to the removal of the entire mitochondrial
network through programmed cell death, thus conserving overall
fidelity of the host organism
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Krebs cycle, is especially prone to oxidative damage. This
is due to the presence of an iron–sulfur cluster in the active
center of aconitase making this enzyme sensitive to inac-
tivation by reactive oxygen.
Stemming from the endosymbiotic origin of mito-
chondria, quality control in the matrix is performed by
specialized, bacterial-type proteases, namely Lon and ClpX
[122]. Lon belongs to the family of AAA? ATPases and
forms homomeric complexes enclosing a proteolytic
chamber analogous to cytosolic proteasomes. Lon is impli-
cated in the clearance of oxidized, carbonylated proteins
from the mitochondrial matrix with inactivated aconitase
being a major substrate [94]. In several aging models, an
age-dependent decrease in Lon activity was found [15]. Loss
of Lon activity over time causes the accumulation of dam-
aged aconitase, thus severely impacting mitochondrial
energy production. Interestingly, overexpression of Lon in a
fungal aging model caused considerable healthspan exten-
sion accompanied by an increased resistance to oxidative
stress and a decrease in carbonylated aconitase [83]. To date,
no distinct neurodegenerative disorder is connected to Lon.
However, it is tempting to speculate that a loss of Lon
activity, and thus a decline in mitochondrial health during
aging, might be a contributing or modifying factor triggering
neurodegenerative processes. Mitochondria already under
stress due to mutational alteration of key factors might
depend on Lon protease activity to buffer against mito-
chondrial dysfunction during preclinical stages of
neurodegenerative disorders.
Ubiquitin-dependent degradation of mitochondrial
proteins
While mitochondrial protein turnover was long thought to
be the domain of intramitochondrial specialized proteases,
a role for the ubiquitin (Ub)-proteasome system (UPS) in
maintaining mitochondrial function is now generally
accepted [82]. The attachment of the small protein Ub to
proteins, ubiquitination, is a versatile regulatory signal.
Ubiquitination is a three-tiered process involving the action
of Ub-activating (E1) and Ub-conjugating enzyme (E2s),
and finally, Ub ligases (E3s), which confer substrate
specificity to the final Ub transfer [32]. In most cases,
ubiquitination enables, as well as causes, the recognition
and subsequent proteolytic degradation of substrate pro-
teins by the proteasome, a large cytosolic protease
complex. The mitochondrial matrix, intermembrane space
and IMM are devoid of ubiquitination machinery; however,
several recently identified E3 Ub ligases residing in the
OMM target mitochondrial proteins for Ub and protea-
some-dependent degradation [71, 93]. In addition to the
OMM-anchored E3s, soluble cytosolic Ub ligases such as
Parkin (in-depth discussion by Winklhofer in the same
issue) also act on mitochondrial proteins [72].
Analogous to the endoplasmic reticulum (ER), where
damaged, misfolded or superfluous proteins are cleared
through the ER-associated degradation (ERAD) pathway,
mitochondrial proteins are under the surveillance of the
OMM-associated degradation (OMMAD) pathway [93].
Ub ligases currently known to play a role in mitochondrial
maintenance are the RING finger proteins MARCH5/
MITOL, MULAN, RTM9 (our unpublished observation) as
well as in-between-RING-proteins IBRDC2 and Parkin
[10, 16, 71, 121, 140]. There are striking parallels between
the ER and mitochondria in terms of their molecular
machineries for Ub-dependent protein degradation. Both
the mitochondria and the ER harbor membrane-anchored
RING finger Ub ligases facing the cytosol in a position to
engage the UPS localized in the cytoplasm. The interiors of
both organelles are devoid of ubiquitination machinery
as well as proteasomes. In addition, the ERAD and the
OMMAD pathways depend on the action of p97/valosin-
containing protein (VCP). It was recently shown that p97 is
involved in the retrotranslocation of ubiquitinated proteins
from mitochondria [135]. The AAA-ATPase p97 forms
hexameric rings which provide the necessary energy to
extract ubiquitinated proteins from or transport them across
Fig. 2 Mitochondrial protein quality control. Each of the four
mitochondrial compartments is under the surveillance of proteolytic
machineries. Mitochondrial matrix proteins are degraded by bacterial-
type Lon protease and by proteases anchored to the IMM. Proteases of
the AAA-type, anchored inside the IMM and facing the matrix and
the IMS compartment are responsible for degradation of membrane-
anchored proteins of the IMM, the matrix as well as the IMS. OMM-
anchored ubiquitin ligases cause the degradation of OMM and
potentially IMS localized proteins through a process termed OMMAD
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membranes for proteasomal degradation [26]. Interestingly,
mutations in p97 were found to be causative for inclusion
body myopathy with Paget disease of bone and fronto-
temporal dementia (IBMPFD), pointing to an important
role of p97 in neuronal survival [64, 132]. While ERAD is
a well-studied protein degradation mechanism, research
into the OMMAD pathway and its role in mitochondrial
protein quality control is still in its infancy. Interestingly,
certain neurodegenerative disorders are linked to failed
clearance of proteins from mitochondria. ALS might be
influenced by the OMMAD Ub ligase MARCH5 [136] and
mutated superoxide dismutase 1 (mSOD1) has been linked
to some forms of familial ALS. Mislocalization of mSOD1
to mitochondria seems to be a key factor for some of the
familial forms of ALS [69, 80, 128]. While there is still
controversy about the mechanism by which mSOD1 exerts
its deleterious effects, MARCH5 was recently shown to
cause the degradation of mSOD1, while MARCH5
knockdown by RNAi caused the stabilization of mSOD1
thus exacerbating cellular damage [136].
Besides its role in the degradation of mSOD1, MARCH5
is also involved in blunting polyQ toxicity. Expansion of a
polyQ track in ataxin-3 causes Machado-Joseph (MJD), a
neurological disease with late onset characterized by ataxia.
It was recently shown that expression of MARCH5 reduces
the accumulation of polyQ in mitochondria by inducing its
ubiquitination and subsequent proteasomal degradation.
Furthermore, knockdown of MARCH5 induced polyQ
aggregate formation subsequently causing cytochrome c
release and cell death [119]. However, MARCH5 is not
only involved in the quality control of mutated proteins
localized to mitochondria. Mitochondrial fission is also
impacted by MARCH5 through increased recruitment of the
fission protein Drp1 to mitochondrial scission sites fol-
lowing MARCH5 mutant expression [71]. Thus, MARCH5
seems to integrate two distinct mitochondrial quality con-
trol mechanisms: Ub-dependent protein degradation and
maintenance of mitochondrial dynamics.
While MARCH5 is the first identified and best studied
mitochondrial Ub ligase, other on mitochondria acting E3
Ub ligases were recently described. One of these mito-
chondrial Ub ligases, IBRDC2 [10], belongs to the class of
in-between-ring RING finger proteins characterized by a
RING finger domain flanked on both sides by additional
RING fingers. IBRDC2 was recently found to be involved
in the regulation of Bax-dependent programmed cell death
[10]. This puts IBRDC2 in the pathway of mitochondrial
quality control on the cellular level. Although no direct
connection between IBRDC2 and mitochondrial dysfunc-
tion during neurodegeneration has been established to date,
the involvement of this Ub ligase in apoptosis regulation
makes this protein an interesting candidate and target for
further studies.
A third E3 enzyme found to be integral to the OMM is
MAPL/GIDE/MULAN (will be referred to as MAPL
thereafter). MAPL was reported to promote ubiquitination
as well as sumoylation of substrate proteins. MAPL is
involved in NF-jB signaling and regulation of mitochon-
drial fission through the sumoylation of Drp1 [16], as well
as programmed cell death [140]. In addition, MAPL was
found to regulate a novel vesicle-based, cargo-selective
transport route between mitochondria and peroxisomes
[91].
The study of mitochondrial ubiquitin ligases and the
degradation pathways governed by them is still in its
infancy. Further research is needed to evaluate the
molecular mechanisms and general importance of these
proteins in maintaining mitochondrial function.
Protein processing and degradation on the IMM
The well-established connections between protein degrada-
tion and/or processing on the inner mitochondrial membrane
IMM and neurodegeneration highlight the importance of
protein quality control on this protein-richest cellular
membrane. Mitochondrial protein turnover and processing
on the IMM rely on specialized membrane-anchored prote-
ases part of a highly conserved family of AAA proteases and
evolutionary akin to the bacterial FtsH protease [84]. These
proteins are the IMS-facing i-AAA and the matrix-facing
m-AAA proteases. In mammals, the i-AAA protease is
composed of homo-oligomeric hexameric complexes
formed by YME1L. In humans, m-AAA protease has a
hexameric ring-like architecture made of either a hetero-
meric complex consisting of the subunits paraplegin and
AFG3L2 or a homomeric complex containing only AFG3L2
subunits [55]. Notably, dysfunctions of the m-AAA protease
have been linked to neurodegenerative diseases such as
hereditary spastic paraplegia (HSP) [22] and a form of
dominant spinocerebellar ataxia [42]. Autosomal dominant
spinocerebellar ataxias (SCA) are a heterogeneous group of
neurological diseases associated with cerebellum degener-
ation causing progressive gait, imbalance and limb ataxia.
SCA28 associated with mutations in the AFG3L2 gene
accounts for around 3% of SCA cases and is the only dom-
inant ataxia associated with mitochondrial dysfunction so far
[42]. Localization studies, where AFG3L2 was found to be
highly expressed in Purkinje cells and the large neurons of
the deep cerebellar nuclei, correlate the disease symptoms
with an important function of AFG3L2 in these neurons. In
addition, this tissue-specific expression of AFG3L2 might be
due to a specific protein quality control need for highly
complex neurons such as Purkinje cells, which can be pro-
vided only by high levels of AFG3L2, which might also
explain the highly selective neurological damage associated
with SCA28.
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The second neurological disorder involving the m-AAA
protease is associated with autosomal recessive mutations
in the SPG7 gene coding for paraplegin accounting for
around 5% of cases of HSP [22]. Progressive and cell-
specific axonal degeneration is a characteristic of HSP. In
its pure form, HSP is characterized by slowly progressive
spasticity and weakness of the limbs, with occasional mild
peripheral neuropathies [12]. Additional symptoms of HSP
may include cortical and cerebellar atrophy, amyotrophy,
peripheral neuropathy, optic atrophy, deafness, as well as
mental retardation [106]. The involvement of paraplegin
connects defective mitochondrial proteolysis and/or pro-
cessing with axonal degeneration. As for the pathogenesis
of the paraplegin-associated HSP, whether the processing
of a specific substrate or a general proteolytic defect is
responsible for the observed axonal degeneration is not
entirely clear. A defect in mitochondrial ribosome assem-
bly and thus mitochondrial protein translation was
suggested based on the observation of impaired processing
of MRPL32 in paraplegin-deficient mice [96]. MRPL32 is
a subunit of the 70S mitochondrial ribosome and as such
essential for the translation of the mtDNA-encoded sub-
units of the ETC. While this is an interesting potential
disease mechanism, paraplegin-containing m-AAA prote-
ase is also involved in the processing and degradation of
other proteins such as OPA1 as discussed below in a dif-
ferent context.
Disturbed mitochondrial morphology is involved
in neurodegeneration
The mitochondrial fission and fusion machineries are dee-
ply integrated into cellular physiology, and consequently,
mutations in mitochondrial morphogens do not only result
in aberrant morphology of the organelles, but are causally
associated with a wide spectrum of neuropathologies.
Regulation of mitochondrial dynamics
Unlike the classical textbook picture of a static bean-
shaped organelle living a solitary life in the cytosol,
mitochondria display a more dynamic behavior [99, 111,
133]. Most cells contain, at any given time, potentially
hundreds of individual mitochondria. However, this
organellar individuality is mostly short lived. Due to con-
stantly ongoing, antagonistically acting fusion and fission
events (Fig. 3), mitochondria form dynamic networks that
are constantly reshaped to meet diverse cellular demands.
Two separate molecular machineries govern mitochon-
drial morphology and dynamics. The coordinated fusion of
the OMM and IMM is achieved by the concerted action
of large GTPases [33]: whereas the OMM localized
mitofusins Mfn1 and Mfn2 are important for organelle
tethering and fusion of the OMM [77, 108], OPA1 [40],
localized to the IMM and the intermembrane space, regu-
lates fusion of the IMM. Mitochondrial fission is also
governed by a large GTPase, the dynamin-related protein
Drp1 [103], which is capable of forming custom-tailored
spirals around mitochondria that can constrict and mediate
mitochondrial division [66]. While the mitochondrial
fusion proteins are membrane-bound, Drp1 is cytosolic and
its mitochondrial association and activity in mammalian
cells depends on various accessory proteins [54, 70, 98,
101]. Drp1 is also regulated by posttranslational modifi-
cation [16, 24, 25, 30, 63, 120] as discussed in detail in the
accompanying review by Oettinghaus and colleagues.
One can imagine the highly fused mitochondria as a sys-
tem of power lines connecting the various cellular
compartments, allowing for the rapid transport of energy in
the form of the mitochondrial membrane potential required
for a balanced production of ATP across the cell. On the other
hand, fission of mitochondria produces small, mobile power
units that can easily be transported to sites of high energy
demand which the long, less mobile power lines cannot
reach, for example neuronal synapses [68]. Through axonal
transport small, highly efficient mitochondria are moved
toward synapses, while inefficient or damaged mitochondria
can be brought back to the soma either for repair or auto-
phagic removal [86]. Taking this perspective, it also becomes
apparent that disturbances in maintaining mitochondrial
dynamics and/or transport mechanisms might severely
impact cellular survival, especially that of neuronal cells [76].
The mitofusin Mfn2 and neurodegeneration
The connection between mitochondrial fission and neuro-
degeneration is discussed in depth by Oettinghaus and
Fig. 3 Mitochondrial morphogens. Fission and fusion of mitochon-
dria in mammalian cells are governed by large GTPases. Concerted
fusion of the two mitochondrial membranes is performed by the
action of the OMM localized mitofusins Mfn1 and Mfn2, and the
IMM and IMS resident Opa1 protein. Mitochondria are divided by
the action of the dynamin-related GTPase Drp1 after recruitment to
the OMM by accessory factors. Several regulatory mechanisms are in
place to shape the mitochondrial network according to cellular
demand. Ubiquitin-dependent degradation of mitofusins and proteo-
lytic processing of Opa1 modulate mitochondrial fusion rates
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colleagues in the same issue. Thus, we restrict our dis-
cussion to mitochondrial fusion processes and their
connection to neurodegenerative disorders. Mutations in
the mitofusin Mfn2 are causally linked to the development
of Charcot-Marie-Tooth disease Type 2A (CMT2A) [141].
CMT is a common, inherited peripheral neuropathy
affecting motor as well as sensory neurons. In CMT2A, an
autosomal-dominant inherited, axonal CMT subtype, the
severity of the disease varies, with some patients addi-
tionally developing hearing loss and optic atrophy
depending on the underlying Mfn2 mutation [31]. Inter-
estingly, although Mfn1 and Mfn2 share significant
sequence homology with each other, no connections
between mutations in Mfn1 and CMT have been reported.
While it has been suggested that mutated Mfn2 acts in a
dominant-negative manner [8], it is still somewhat unclear
how these mutations lead to neurodegeneration. Studies on
patient-derived fibroblasts carrying certain Mfn2 muta-
tions did not reveal obvious changes in mitochondrial
morphology [4]. Mfn1 can compensate for such mutations
through the formation of fusion-competent heteromeric
wildtype Mfn1/mutated Mfn2 complexes. Thus, tissue-
specific lack of Mfn1 expression might explain the
observed effect on mitochondrial morphology and disease
development. Alternatively, changes in Mfn2 activity
might be subtle and might manifest themselves in certain,
exquisitely sensitive tissues and only after extended peri-
ods of time, as seen for some CMT2A patients with late
onset and mild symptoms, where the typical manifestation
age is between 10 and 50 years [31]. This notion is sup-
ported by observations made in budding yeast where only
one mitofusin ortholog, Fzo1, exists: expression of Fzo1
modified to harbor equivalent pathogenic Mfn2 mutations
leads to severe impairment of fusion activity, accompanied
by changes in protein stability associated with such Mfn2
mutations [5]. Interestingly, mitochondrial fusion is
important for maintaining respiratory competence. Com-
plete loss of mitochondrial fusion activity through Fzo1
deletion results in loss of mtDNA and the development of
a petite phenotype in yeast [104]. In mice, severe
impairment of fusion through the deletion of Mfn1 or
Mfn2 results in the partial loss of mtDNA in fibroblasts. In
addition, aberrant mitochondrial morphology in Purkinje
cells from mfn2-/- mice is accompanied by impaired
dendritic outgrowth and spine formation, ultimately
resulting in the degeneration of these cells [27, 28]. Lastly,
it should be mentioned here that Mfn2 (but not Mfn1) is
also expressed on endoplasmic reticulum (ER) mem-
branes, forming a bridge between mitochondria and the
ER, essential for Ca2? homeostasis [39, 114]. However,
up to now, impaired calcium signaling due to Mfn2
mutations has not been implicated with CMT2A
pathogenesis.
OPA1 processing and disease
Mitochondrial fusion is impacted on the posttranslational
level by the ubiquitin-dependent turnover of mitofusin [92,
93, 121], as well as the proteolytic processing of OPA1
[45]. Furthermore, proteolytic processing of OPA1 also
appears to be important for cellular and in particular neu-
ronal homeostasis. OPA1 resides in the mitochondrial
intermembrane space and is involved in IMM fusion, as
well as in the regulation of mitochondrial cristae mor-
phology [34, 79, 97]. Inhibition of OPA1 leads to
spontaneous apoptosis, indicating that mitochondrial fusion
and/or cristae regulation by this protein are critical for the
control of mitochondrial steps in apoptosis [79, 97]. Human
mitochondria contain at least eight OPA1 isoforms that
arise from alternative splicing, generating OPA1 isoforms
that also contain sites for proteolytic processing generating
even more shorter OPA1 isoforms [41, 67]. Present in
approximately equal proportions, balanced expression of
long and short OPA1 isoforms is required for mitochon-
drial fusion [116]. The pattern of OPA1 isoforms, and,
therefore, OPA1 processing, strongly depends on the
functional competence of mitochondria. Consistent with
this notion, the dissipation of the mitochondrial membrane
potential (Dwm), or mitochondria-targeting apoptotic
stimuli induce OPA1 cleavage, the loss of long isoforms,
and thus, subsequent inhibition of mitochondrial fusion
[43, 59]. The link between functional integrity of mito-
chondria, OPA1 processing and mitochondrial fusion
suggests that proteostasis of OPA1 might be central for
coordinating mitochondrial deterioration, including the
dissipation of Dwm together with the activation of mito-
chondrial quality control mechanisms. Indeed, it has been
suggested that fusion-deficient mitochondria are separated
from the dynamic network of these organelles to facilitate
their efficient mitophagic removal [126].
The generation of the various OPA1 isoforms through
proteolytic processing is a field of intense research. The
proteolytic processing of OPA1 (Mgm1 in yeast) is a
conserved process from yeast to human; however, its role
and especially the proteases involved differ [84]. Most
likely due to the additional roles OPA1 has acquired,
especially the anti-apoptotic function, several proteases are
involved in OPA1 processing in mammals. OPA1 possess
three protease cleavage sites, one of which is only present
after alternative splicing. While all OPA1 variants contain
a recognition site for metallopeptidase for the removal of
the mitochondrial targeting sequence and the m-AAA
protease S1 cleavage site, OPA1 splice variants that
include alternative exon 5b contain an additional i-AAA
protease S2 cleavage site. It was found that homo-oligo-
meric m-AAA protease isoforms containing AFG3L2
appear to be more efficient in OPA1 processing than
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paraplegin-containing isoforms of this protease [84].
However, paraplegin seems to have a role in OPA1 pro-
cessing which might be crucial under certain conditions or
certain tissues, e.g., neurons. Recently, OMA1, another
mitochondrial protease, was linked to OPA1 processing,
independently from the m-AAA protease during mito-
chondrial dysfunction [45, 62]. The role of the rhomboid-
like protease PARL in OPA1 processing, based on studies
in budding yeast suggested to be a processing protease for
OPA1, however, is still debated [34, 59].
OPA1 mutations are linked to about 60% of autosomal
dominant optic atrophy (ADOA) cases [3, 40]; the most
common inherited optic atrophy. ADOA is characterized
by vision impairment resulting from loss of retinal gan-
glion cells. Notably, ADOA shows marked variations in
clinical phenotypes and varying degrees of vision loss,
even among siblings carrying identical mutations in OPA1.
Thus, one might speculate that mitochondrial defects,
including mtDNA mutations or abnormal mitochondrial
ROS generation could serve as an additional trigger leading
to optic nerve loss in OPA1 mutation-linked ADOA. Since
mitochondrial oxidative phosphorylation compensation
may preserve vision in patients with OPA1-linked ADOA
[127], disease-linked OPA1 mutations likely affect the
activity of ETC. Whether this is due to inhibition of
mitochondrial fusion changes in mitochondrial cristae
morphology, or a more direct effect on the ETC remains to
be established. However, in contrast to OPA1 protein
depletion that results in almost complete inhibition of
mitochondrial fusion, ADOA-linked mutations have no or
only mild effects on this process [139]. Aberrant OPA1
processing, namely decreases in long isoforms of this
protein, as well as abnormal mitochondrial network orga-
nization also occur in a genetic model of premature aging
(the ‘‘mutator mouse’’ that is expressing a proof-reading-
deficient mutant of mtDNA polymerase-c [43]), suggesting
a more common role for OPA1 in aging and disease.
The mechanisms by which lowered fusion of mito-
chondria and/or abnormal cristae structure could affect
organelle function are not yet understood within the
complex as a whole. Yet, the high rates of mitochondrial
network remodeling, including fusion of these organelles,
have been thought to facilitate the complementation of
mtDNA. Likely, mitochondrial fusion could serve as a
mechanism of mitochondrial quality control by eliminat-
ing locally concentrated defects in mitochondrial proteins
by diluting them, in a similar manner as mtDNA mutations
are complemented. Reciprocally, abnormally lowered
fusion of mitochondria could lead to an increase in the
local abundance of oxidatively modified macromolecules.
Therefore, it is likely that minor defects in mitochondrial
fusion might lead to partial degeneration of mitochondria
in affected cells, and only cells particularly sensitive to
mitochondrial dysfunction would display more severe
phenotypic changes.
Interestingly, mutations of paraplegin, an m-AAA pro-
tease that is required for mitochondrial processing of OPA1
[67] have been linked to HSP [46, 134]. Around 5% of
cases of HSP are caused by mutations in SPG7, encoding
paraplegin. In its pure form, HSP is characterized by
slowly progressive spasticity and weakness of leg and hip
muscles [51], with occasional mild peripheral neuropa-
thies. As in ADOA, severity of symptoms and age of onset
can vary widely, even within the same family. The link
between paraplegin mutations and OPA1 processing in the
development of the disease needs to be further clarified.
However, a number of proteases, including YME1 [60,
116], peptidase OMA1 [45, 62], and m-AAA protease
subunits other than paraplegin [44], can also mediate OPA1
processing, suggesting that the mechanism of OPA1 pro-
cessing may vary between different cells and be regulated
by distinct stimuli. Furthermore, abnormal processing of
other m-AAA protease substrates besides OPA1 might also
be critical for spastic paraplegia pathogenesis.
The prevalence of optic nerve degeneration
among mitochondrial disorders
When considering mitochondrial maintenance and function
in connection to neurodegenerative disorders, the very
common and often most prominent involvement of the
Fig. 4 Distribution of mitochondria around the optic nerve head. A
section of human nerve was stained with anti-Cox4 antibodies to
assess mitochondrial distribution. Shown is the optic nerve head with
the retinal layers on the top. Note the strong Cox4 reactivity in the
nerve fiber layer (NFL) before and especially after the axon left
the globe (asterisk) and crossed the lamina cribrosa (LC). Also note
the sharp decline in mitochondrial staining along the optic nerve. This
coincides with the region where myelination of the optic nerve begins
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optic nerve is striking. LHON and ADOA are mono-
symptomatic and restricted to retinal ganglion cell (RGC)
death. For other more complex syndromes, such as Leigh’s
disease, MELAS, or MERRF, vision loss due to RGC
degeneration is reported [21]. In addition, careful exami-
nation of patients suffering from CMT2A and Friedreich’s
ataxia, as well as Mohr-Tranebjerg syndrome, revealed
optic nerve involvement. Why RGCs are especially vul-
nerable to disturbances in mitochondrial dysfunction is still
debated. Current models of optic neurodegeneration con-
nected to mitochondrial dysfunction cite the special
architecture of RGCs with mitochondria-enriched, non-
myelinated parts in the retina and the optic nerve head and
comparably mitochondria-poor, myelinated tracts along the
optic nerve (Fig. 4). It seems plausible to postulate that
maintaining this mitochondrial gradient requires high
fidelity on all levels of mitochondrial maintenance, namely
fission/fusion, transport and biogenesis. In addition, com-
pensatory mechanisms potentially active in other cell types
might not be available under these circumstances. While
increased mitochondrial mass may be sufficient to alleviate
minor deficiencies in energy production due to mutations in
the ETC, the already high local concentration of mito-
chondria in the unmyelinated part of RGCs might not allow
for such a mechanism.
Another interesting aspect is the often less well-defined
set of clinical manifestations of the above-mentioned dis-
eases, which often feature a remarkable phenotypic
overlap. For example, carriers of OPA1 mutations might
present with the classical features of ADOA but may also
present with peripheral neuropathy as seen in CMT or
neurological symptoms as reported for HSP patients. The
same is true of LHON and ADOA. While LHON normally
follows an acute course and ADOA presents as a slowly
progressive optic neuropathy, certain LHON cases follow
the ADOA pattern of neuropathy while there are reports of
ADOA patients with acute vision loss. These findings again
highlight the shared common mitochondrial dysfunctions
that might manifest themselves in different ways based on
other genetic or environmental modifiers (Fig. 5). In
addition, these shared common features might allow gen-
eralizing findings based on the study of these different
disease entities and lead to a better understanding of neu-
rodegenerative processes.
Fig. 5 Attack points of mitochondrial diseases. Protein degradation,
balanced mitochondrial morphology and mitophagy promote the
maintenance of a high fidelity, respiratory-competent mitochondrial
network. Disturbances in mitochondrial morphology, impaired ETC
through either acquired or inherited mtDNA mutations, as well as
protein damage through oxidative stress cause damage to the
mitochondrial network. The impact points of various neurodegener-
ative diseases and their direct and also indirect effects on
mitochondrial health are illustrated. Mitochondrial protein degrada-
tion and processing is directly affected by disease mutations in SPG7/
paraplegin (mutated in hereditary spastic paraplegia) and AFG3L2
(mutated in spinocerebellar ataxia). Protein damage and oxidative
stress are increased in patients suffering from Friedreich’s ataxia (FA)
and amyotrophic lateral sclerosis (ALS). Inherited and also acquired
mtDNA mutations impact the fidelity of the ETC in MELAS
(mitochondrial encephalopathy, lactic acidosis, and stroke-like epi-
sodes), MERRF (myoclonic epilepsy with ragged red fibers), LHON
(Leber’s hereditary optic neuropathy) but also familial PD (Parkin-
son’s disease). In addition, ETC function is indirectly affected via
disturbed mitochondrial morphology in ADOA (autosomal dominant
optic atrophy) as well as CMT2A (Charcott–Marie-Tooth Type 2A)
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Conclusions
Mitochondrial dysfunction is at the heart of neurodegener-
ative processes. The long-held belief that defects in
mitochondrial respiration are responsible for the degener-
ation and death of neurons during the course of most, if not
all, neurodegenerative disorders is now being expanded by
integrating more mitochondrial functions. While bioener-
getics and associated oxidative stress are still crucial to the
etiology of neurodegenerative diseases, mitochondrial
protein quality control, mitochondrial dynamics and pro-
grammed cell death pathways need to be integrated for a
more comprehensive understanding of the link between
mitochondrial dysfunction and neurodegeneration. With the
understanding of the fundamental pathogenetic mechanisms
leading to neurodegeneration, a clearer picture of differ-
ences and similarities between different clinical disease
entities emerges. In addition, the oftentimes striking degree
of phenotypic expression of disease causing mutations and
the symptomatic overlap between different diseases will
likely be better understood with further acquisition of in-
depth knowledge of the underlying mechanisms involving
mitochondrial maintenance. In the future, an even more
integrative view of mitochondrial dysfunction in the context
of neurodegeneration is imperative for the successful
development of effective treatment strategies aimed at
combating common neurodegenerative diseases.
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